[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519819":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":53,"collaborators":55,"id":58,"slug":19,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":19,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pregnant women","EXPERIMENTAL","Pregnant women, with gestational age at inclusion \\\u003C28 weeks of amenorrhea, with or without risk factors for GDM will be included in the first consultation at the Maternity Hospital (Bordeaux University Hospital).\n\nDetermination of glycation markers (HbA1c, glycated albumin, and skin autofluorescence).",[13],"Diagnostic Test: Pregnant women",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","Gestational Diabetes Mellitus increases the risk of adverse pregnancy outcomes (such as macrosomia).\n\nThe lack of early clinical symptoms leads to screen pregnant women for GDM, and the strategies of screening are a matter of debate.\n\nInterventions to control glucose levels in women with GDM have demonstrated efficacy in terms of macrosomia. However, macrosomia may start before the time of screening, suggesting that markers of glycation may have interest : skin autofluorescence, glycated albumin.",[9],null,[21,27],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"FOUSSARD NINON, Dr","CONTACT","5.57.65.60.78","+33","ninon.foussard@u-bordeaux.fr",{"name":28,"role":23,"phone":24,"phoneExt":25,"email":29},"RIGALLEAU VINCENT, Pr","vincent.rigalleau@chu-bordeaux.fr",[31],{"facility":32,"status":33,"city":34,"state":19,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Hopital Pellegrin","RECRUITING","Bordeaux","33000","France","FR",{"type":39,"coordinates":40},"Point",[41,42],-0.58046,44.84124,{"lat":42,"lon":41},[45,46,50],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},{"name":47,"role":23,"phone":48,"phoneExt":25,"email":49},"MILAN LEA","5 57 82 07 38","lea.milan@chu-bordeaux.fr",{"name":51,"role":52,"phone":19,"phoneExt":19,"email":19},"SENTILHES LOIC, Pr","PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[56],{"name":57,"class":6},"Société Francophone du Diabète","100519819",false,"NCT06048510","New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.","GLYCAGEST","Inclusion criteria:\n\n1. Age ≥ 18 years\n2. Singleton pregnancy (or twin pregnancy reduced spontaneously or medically before 14 weeks of amenorrhea)\n3. Gestational age at inclusion \\\u003C28 weeks of amenorrhea\n4. Participant affiliated with or beneficiary of a social security scheme\n5. Collection of patient consent.\n\nExclusion criteria:\n\n1. Gestational age at inclusion ≥ 28 weeks of amenorrhea\n2. Multiple pregnancy\n3. Known diabetes prior to pregnancy\n4. History of bariatric surgery\n5. Expected delivery in another maternity unit not participating in the study\n6. Person deprived of liberty by judicial or administrative decision\n7. Guardianship or curatorship\n8. Participant not affiliated or not benefiting from a social security scheme.","ALL","18 Years","99 Years",{"count":68,"type":69},800,"ESTIMATED","INTERVENTIONAL",[72],"NA","Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs. selective, and macrosomia may begin before the time of screening, suggesting that glycation markers may have an interest. The objective of this trail is to compare novel markers: skin autofluorescence and glycated albumin, to HbA1c (reference) as predictors of GDM, macrosomia and other adverse outcomes, in pregnant women.",[75,76],"Macrosomia, Fetal","Gestational Diabetes Mellitus in Pregnancy",[78,79,80,81,82,83],"skin autofluorescence","glycated albumin,","HbA1c","glycation biomarkers","macrosomia","gestational diabetes mellitus","2026-01-13",{"date":86,"type":87},"2026-01-15","ACTUAL",{"date":89,"type":87},"2023-12-18",{"date":91,"type":69},"2028-09",{"name":5,"class":6},1]